Prognosis of High Dose Chemotherapy/Autologous Bone Marrow Transplantation Candidates not Receiving This Treatment after Failure of Primary Therapy of Hodgkin's Disease

References

• Ahmed T., Ciavarelle D. High-dose potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. Leukemia 1989; 3: 19–22
   PubMed Web of Science ®Google Scholar
• Andrien J.-M., Ifrath N., Payen C., Fermanian J., Coscas Y., Flandrin G. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J. Clin. Oncol. 1990; 8: 1148–1154
   PubMed Web of Science ®Google Scholar
• Applebaum F. R., Sullivan K. M., Thomas E. D., et al. Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. J. Clin. Oncol. 1986; 3: 1490–1494
   Web of Science ®Google Scholar
• Bergsagel D. E. Salvage treatment for Hodgkin's disease in relapse. J. Clin. Oncol. 1987; 5: 525–526
   PubMed Web of Science ®Google Scholar
• Biermann P. J., Jagannath S., Dicke K. A. High dose cyclophosphamide, carmustine and etoposide (CBV) in 128 patients (pts) with Hodgkin's disease. Blood 1988; 72: 239A
   Google Scholar
• Bonadonna G., Valagussa P., Santoro A. Alternating non-cross resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann. Intern. Med. 1986; 104: 739–746
   PubMed Web of Science ®Google Scholar
• Brice P., Ferme C., Marolleau J. P., Oksenhendler E., Dombret H., Adam M., Gerota O., Gisselbrecht C., Riihl Georgii U. A., Hiller E., Gerhartz H. High dose therapy with autologous bone marrow or peripheral stem cell transplantation in 40 patients with advanced Hodgkin's disease. Proc. 2nd Int. Symp. on Hodgkin's disease. Köln 1991; 48A
   Google Scholar
• Carella A. M., Santini G., Congiu A., Nati S., Marti-Ncngo M, Giordano D., Sessarego C, Raffo M. R., Danasio E., Marmont A. M. Autologous bone marrow transplantation (ABMT) in the treatment of 25 advanced resistant Hodgkin's disease patients. Proc. 3rd Int. Conf. Lugano 1987; 94, A.on malignant lymphoma
   Google Scholar
• De Vita V. T., Simon R. M., Hubbard S. M. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann. Intern. Med. 1980; 92: 587–595
   PubMed Web of Science ®Google Scholar
• Diehl V., Pfreundschuh M., Loftier M., Smith K., Rühl U., Georgii A., Hiller E., Gerhartz H. Thera-piestudien der deutschen Hodgkin-Studiengruppe. Onkolog. 1987; 10: 62–66
   PubMedGoogle Scholar
• Fisher R. I., de Vita V. T., Hubbard S. M., et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med. 1979; 90: 761–763
   PubMed Web of Science ®Google Scholar
• Fox K. A., Lippmann S. M., Cassady J. R., Heusinkveld R. S., Miller T. P. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. J. Clin. Oncol. 1987; 5: 38–45
   PubMed Web of Science ®Google Scholar
• Gams R. A., Omura G. A., Velez-Garcia E., Kellermeyer R., Raney M., Bartolucci A. A. Alternating sequential combination chemotherapy in the management of advanced Hodgkin's disease. Cancer 1986; 58: 1963–1968
   PubMed Web of Science ®Google Scholar
• Goldstone A. H. EBMT experience of autologous BMT (ABMT) in non-Hodgkin's disease. Bone Marrow Transplant 1986; 1(Suppl. 1)289–292
   Google Scholar
• Gribben J. G., Linch D. C. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340–344
   PubMed Web of Science ®Google Scholar
• Hagemeister F. B., Tannir N., McLaughlin P. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J. Clin. Oncol. 1987; 5: 556–561
   PubMed Web of Science ®Google Scholar
• Hagenbeek A., van Putten W. L. J. Autologous bone marrow transplantation in patients with primarily refractory or early relapsing Hodgkin's disease. Proc. 2 Int. Symp. on Hodgkin's disease. Köln 1991; 49A
   Google Scholar
• Henry-Amar M., Somers R. Survival outcome after Hodgkin's disease: A report from the International Data Base on Hodgkin's disease. Semin. Oncol. 1990; 17: 758–768
   PubMed Web of Science ®Google Scholar
• Hoppe R. T. Development of effective salvage treatment programs for Hodgkin's disease: An ongoing clinical challenge. Blood 1991; 77: 2093–2095
   PubMed Web of Science ®Google Scholar
• Jagannath S. J., Armitage J. O., Dicke K. A. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 1989; 7: 179–185
   PubMed Web of Science ®Google Scholar
• Mauch P., Balikian J., Rosenthal D., Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J. Clin. Oncol. 1985; 3: 637–640
   PubMed Web of Science ®Google Scholar
• Jones R. J., Piantadosi S., Mann R. B., Ambinder R. F., Seifter E. J., Vriesendorp H. M., Abeloff M. D., Burns W. H., Stratford May W., Rowley S. D., Vogelsang G. B., Wagner J. E., Wiley J. M., Wingard J. R., Yeager A. M., Saral R., Santos G. W. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 1990; 8: 527–537
   PubMed Web of Science ®Google Scholar
• Kaplan H. S. Hodgkin's disease 2nd ed. Harvard University Press, Cambridge 1980
   Google Scholar
• Klimo P., Connors J. M. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin. Hematol. 1988; 25(Suppl. 2)34–40
   PubMed Web of Science ®Google Scholar
• Körbling M., Holle R., Haas R., Knauf W., Dorken B., Ho A. D., Kuse R., Pralle H., Fliedner T. M., Hunstein W. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J. Clin. Oncol. 1990; 6: 978–985
   Google Scholar
• Lohri A., Barnett M., Fairey R. N., O'Reilly S. O., Philips G. L., Reece D., Voss N., Connors J. M. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia. Experience 1970 to 1988. Blood 1991; 77: 2292–2298
   PubMed Web of Science ®Google Scholar
• Longo D. L. The use of chemotherapy in the treatment of Hodgkin's disease. Semin. Oncol. 1990; 17: 718–735
   Google Scholar
• Longo D. L., Duffey P. L., De Vita V. T., Wiernik P. H., Hubbard S. M., Phares J. C., Bastian N. W., Jaffe E. S., Young R. C. Treatment of advanced-stage Hodgkin's disease: Alternating noncrossresistant MOPP/CABS is not superior to MOPP. J. Clin. Oncol. 1991; 9: 1409–1420
   PubMed Web of Science ®Google Scholar
• Marcus R. E., Wimperis J. Z., Apperley J. F., Baglin T. P., Williams M. V. Autologous bone marrow transplantation for Hodgkin's disease-A single centre experience over a three year period. Proc. 2nd Int. Symp. on Hodgkin's disease. Köln 1991; 49A
   Google Scholar
• Mauch P., Tarbell N., Skarin A., Rosenthal D., Weinstein H. Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy. J. Clin. Oncol. 1987; 5: 544–549
   PubMed Web of Science ®Google Scholar
• McMilan A., Goldstone A., Linch D., Gribben J., Chopra R., Taghipour G. 100 cases of relapsed Hodgkin's disease treated with BEAM chemotherapy and ABMT in a single centre. Proc. 4th Int. Conf. on Malignant Lymphoma. Lugano 1990; 28A
   Google Scholar
• Mead G. M., Harker W. G., Kushlan P., Rosenberg S. A. Single-agent palliative chemotherapy for end-stage Hodgkin's disease. Cancer 1982; 50: 829–835
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Connors J., Voss N., Fairey R., Herzig G., Klimo P., Philipps G. Augmented cyclophosphamide, BCNU, and Etoposide (CBV) and autologous bone marrow transplantation (ABMT) in progressive Hodgkin's disease (HD). Proc. 3rd Int. Conf. on Malignant Lymphoma. Lugano 1987; 93A
   Google Scholar
• Petersen F. B., Appelbaum F. R., Hill R., Fisher L. D., Bigelow C. L., Sanders J. E., Sullivan K. M., Bensinger W. I., Witherspoon R. P., Storb R., Clift R. A., Fefer A., Press O. W., Weiden P. L., Singer J., Thomas E. D., Buckner C. D. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J. Clin. Oncol. 1990; 8: 638–647
   PubMed Web of Science ®Google Scholar
• Philip T., Dumont J., Teillet F., Maraninchi D., Gorin N. C., Kuentz M., Harousseau J. L., Marty M., Pinkerton R., Herve P. High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. Cancer 1986; 53: 737–742
   Web of Science ®Google Scholar
• Philipps G. L., Wolff S. N., Herzig R. H. Treatment of progressive Hodgkin's disease with intensive chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086–2092
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M., Schoppe U. D., Fuchs R., Pfluger K. H., Loffler M., Diehl V. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastin, and dacarbazine (ABVD): A multi-center trial of the German Hodgkin's Study Group. Cancer Treat Rep. 1987; 71: 1203–1207
   PubMedGoogle Scholar
• Reece D., Barnett M., Connors J. Augmented cyclophosphamide (C), BCNU (B) and Etoposide (V) = CBV and autologous bone marrow transplantation (BMT) for progressive Hodgkin's disease (HD). Blood 1988; 72: 402A
   PubMedGoogle Scholar
• Roach M., Brophy N., Cox R., Varghese A., Hoppe R. T. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J. Clin. Oncol. 1990; 8: 623–629
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonadonna G., Valagussa P., Zucali R., Viviani S., Villani F., Pagnoni V., Musumeci R., Crippa F., Tesoro J. D., Banfi A. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of BVD plus radiotherapy versus MOPP plus radiotherapy. J. Clin. Oncol. 1987; 5: 27–37
   PubMed Web of Science ®Google Scholar
• Vose J. M., Bierman P. J., Anderson J. R., Weisenburger D., Moravec D. F., Sorensen S., Hutchins M., Dowling M. D., Howe D., Okerbloom J., Langdon R. M., Bascom G. K., Packard W., Pevnick W., Armitage J. O. CHLVPP Chemotherapy with involved field-irradiation for Hodgkin's disease: Favourable results with acceptable toxicity. J. Clin. Oncol. 1991; 9: 1421–1425
   PubMed Web of Science ®Google Scholar
• Yahalom J., Gulati S., Fuks Z. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease. Proc. 4th Int. Conf. on Malignant Lymphoma., Lugano, 1990; 28A
   Google Scholar
• Zulian G. B., Selby P., Milan S. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br. J. Cancer 1989; 631–635
   PubMed Web of Science ®Google Scholar